The Upstate Global Health Institute is currently seeking participants with HIV, who are being treated with Trogarzo (Ibalizumab). This registry study will look at routine healthcare data for 3 years to see how effective and long lasting Trogarzo is, when used in combination with other drugs used to treat adults living with HIV, who have tried multiple HIV medications. No study medications will be administered and no medical procedures will be performed as part of this study. All study information will be collected as part of your routine healthcare.

This is an expanded use protocol for patients diagnosed with a Mycobacterium avium complex (MAC). Sponsored by Novartis, the purpose of this program is to make clofazimine available to appropriate patients following clinical presentation.

The Upstate Global Health Institute is working with a sponsor to develop a new oral drug for RSV. The purpose of this study is to see if the drug is safe and effective when treating RSV. We are seeking participants who are experiencing at least 2 of the following respiratory symptoms such as; cough, cough with phlegm, wheezing or shortness of breath rated as MODERATE. Along with these symptoms the following must pertain to participants:

• Patients ≥ 18 years of age
• The patient has a condition that predisposes them to complications after RSV infection, such as:
  • 75 years old or older
  • 65-74 years old with CHF and/or COPD

• New onset or worsening symptoms which include feeling feverish, headache, neck pain, fatigue, loss of appetite, interrupted sleep, body aches, sore throat, nasal congestions, cough, cough with phlegm, wheezing or shortness of breath no more than 72 hours prior to first visit at research clinic.

The Upstate Global Health Institute is currently seeking individuals between 18-75 years of age and have history of Post-Treatment Lyme disease Syndrome (PTLDS). Lyme disease is a public health crisis in the U.S. It is estimated that over 400,000 cases occur every year with 10-20% of those infected going on to develop PTLDS. there are several thoughts as to why these persistent symptoms happen in some people one of them is that there is a persistent infection. Ceftriaxone is an FDA-approved medication recognized as one of the most potent compounds to kill the agent of Lyme disease, but it isn't used often for Lyme Disease outside of the most severe forms because it is given daily for 30 days. However, it has been shown to reduce fatigue and symptoms for 6 months after receiving the drug. This study is looking to see if dosing of Ceftriaxone every 5 days over a period of 6 weeks will be safe, well tolerated and may be more effective than the placebo for subject with PTLDS.